Maynard Um
-
-
-
-
-
-
-
Insmed (INSM) PT Lowered to $185 at Truist Securities
-
-
-
-
-
-
-
Insmed (INSM) PT Lowered to $212 at BofA Securities
-
-
-
-
-
-
-
Stifel on Insmed (INSM): UTHR trial meeting endpoint removes overhang for INSM
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $213 at BofA Securities
-
-
-
-
-
-
-
Insmed reports successful phase 3b trial for lung disease drug ARIKAYCE
-
-
-
-
-
-
-
Insmed (INSM) PT Raised to $200 at RBC Capital
-
-
-
-
-
-
-
Insmed (INSM) PT lowered to $230 at H.C. Wainwright
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

